HighMark Wealth Management’s Pliant Therapeutics PLRX Stock Holding History

HighMark Wealth Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$189K	Hold	166,224	–	–	0.06%	84
2026 Q1	$209K	Sell	166,224 -4,700	-3%	-$5.93K	0.09%	75
2025 Q4	$209K	Sell	170,924 -48,076	-22%	-$72.2K	0.09%	73
2025 Q3	$324K	Buy	219,000 +78,000	+55%	+$119K	0.14%	60
2025 Q2	$164K	Sell	141,000 -16,500	-10%	-$23.3K	0.08%	84
2025 Q1	$213K	Buy	157,500 +82,500	+110%	+$501K	0.13%	52
2024 Q4	$988K	Buy	75,000 +7,500	+11%	+$102K	0.57%	22
2024 Q3	$757K	Hold	67,500	–	–	0.41%	32
2024 Q2	$726K	Buy	67,500 +25,000	+59%	+$322K	0.44%	30
2024 Q1	$633K	Buy	42,500 +19,000	+81%	+$313K	0.39%	33
2023 Q4	$426K	Buy	+23,500	New	+$357K	0.31%	35

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

HighMark Wealth Management's PLRX Position: Q2 2026 in Review

HighMark Wealth Management held its Pliant Therapeutics (PLRX) position steady in Q2 2026 at 166,224 shares worth $189K. The position accounts for 0.06% of the portfolio, ranked #84.

HighMark Wealth Management first reported a position in PLRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $988K in Q4 2024. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

HighMark Wealth Management held 166,224 shares of Pliant Therapeutics worth $189K as of Q2 2026.
HighMark Wealth Management left its Pliant Therapeutics share count unchanged in Q2 2026.
Pliant Therapeutics made up 0.06% of HighMark Wealth Management's portfolio in Q2 2026, its #84 holding.
HighMark Wealth Management first reported a position in Pliant Therapeutics in Q4 2023 and has held it in 11 quarters since.
HighMark Wealth Management's Pliant Therapeutics position peaked at $988K in Q4 2024.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.